Match!
Filip Janku
University of Texas MD Anderson Cancer Center
463Publications
41H-index
6,864Citations
Publications 471
Newest
Purpose: Physicians are expected to assess prognosis both for patient counseling and for determining suitability for clinical trials. Increasingly, cell-free circulating tumor DNA (cfDNA) sequencing is being performed for clinical decision-making. We sought to determine whether variant allele frequency (VAF) in cfDNA is associated with prognosis. Experimental Design: We performed a retrospective analysis of 298 patients with metastatic disease who underwent clinical comprehensive cfDNA analysis ...
Source
Purpose: Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the maximum tolerated dose (MTD) of tepotinib to determine the recommended phase II dose (RP2D). Experimental Design: Patients received tepotinib orally according to one of three dose‑escalation regimens (R) on a 21-day cycle: R1, 30-400 mg once daily for 14 days; R2, 30-315 mg once daily 3 x /week; or R3, 300-1400 mg once daily. After two cycles, treatment could continue in patien...
Source
Background: The oncogenic mitogen-activated protein kinase (MAPK) pathway is dysregulated in a broad range of cancers through mutations in BRAF, KRAS, NRAS, HRAS and MEK1 genes. ASN007 is a novel, potent and orally bioavailable inhibitor of ERK1/2 kinases (IC50 1-2nM) with a very long target residence time (550 min). Preclinical studies show strong anti-tumor activity in multiple RAS mutant xenograft and PDX models, irrespective of mutation subtype. ASN007 also maintains strong activity in BRAF ...
Source
#1Sneha Berry (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 8
#2Nicolas A. Giraldo (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 4
Last.Philippe L. Bedard (Princess Margaret Cancer Centre)H-Index: 34
view all 91 authors...
After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.
1 CitationsSource
Objective: Ripretinib (DCC-2618) is a kinase switch control inhibitor designed to broadly inhibit KIT and PDGFRA mutations. Based on clinical activity observed in heavily pretreated patients (pts) with GIST in a Phase 1 study (NCT02571036), ripretinib is under evaluation in two Phase 3 studies: INVICTUS (NCT03353753) in ≥4th-line pts and INTRIGUE (NCT03673501) in 2nd-line pts, each at the recommended dose of 150 mg once daily (QD). This abstract reports updated results from the escalation and ex...
Source
Background: Rebastinib is an orally administered, kinase inhibitor targeting the switch pocket of tunica interna endothelial cell kinase (TIE2). TIE2 is primarily expressed in endothelial cells, playing a role in angiogenesis. In addition, TIE2 is expressed in a subset of macrophages, TIE2 expressing macrophages (TEMs), which have pro-angiogenic, pro-metastatic, and immunosuppressive properties. Accumulating evidence suggests that chemotherapies, such as paclitaxel, increase the recruitment and ...
Source
Background: Bimiralisib is a balanced dual panPI3K/mTOR inhibitor, which demonstrated anti-cancer activity in a number of preclinical models. Pharmacokinetic (PK) data suggested that intermittent targeting of the PI3K/mTOR pathway could be preferable to continuous daily dosing. Preclinical models in squamous cell head and neck cancer (SCCHN) demonstrated that NOTCH1 Loss of Function (LoF) mutations were associated with efficacy of bimiralisib and other PI3K inhibitors. Methods: We conducted a fi...
Source
Source
#1Aung Naing (University of Texas MD Anderson Cancer Center)H-Index: 41
#2Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 76
Last.Gauri R. Varadhachary (University of Texas MD Anderson Cancer Center)H-Index: 6
view all 20 authors...
Source
#1Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 41
#2Helen J. Huang (University of Texas MD Anderson Cancer Center)H-Index: 13
Last.Jiri Polivka (Charles University in Prague)H-Index: 13
view all 8 authors...
Source
12345678910